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Background: We sought to identify preoperative factors significantly correlated with survival. We also aimed to
evaluate the validity of the prognostic scores in the Tomita and Tokuhashi systems and discuss several aspects to
improve the predictive accuracy of these systems. Moreover, we suggest modified criteria for selecting treatment
strategies.
Methods: In total, the outcomes of 112 patients with spinal metastasis who underwent surgery between January
2006 and June 2011 were retrospectively reviewed. The validity of the prognostic scores was assessed on the basis
of their correlation with survival. For various primary malignancies, new scoring criteria were applied in each system
according to the survival results obtained in this study. Each revised scoring system was adjusted with a similar
principle of scoring as described previously. Patient survival according to each preoperative factor was analyzed by
the Kaplan-Meier method. The predictive value of each scoring system was evaluated by the log-rank test and Cox
regression analysis.
Results: The interval from the diagnosis of the primary malignancy to that of spinal metastasis (p = 0.023) and
the interval from the diagnosis of spinal metastasis to surgery (p = 0.039) were significantly correlated with survival.
Regarding Tokuhashi scores, the correlation coefficient was 0.790 before adjustment (p = 0.001) and 0.853 after
adjustment (p < 0.001). For Tomita scores, the correlation coefficient was −0.994 (p < 0.001) both before and after
adjustment.
Conclusions: Tomita scores more accurately predicted survival than Tokuhashi scores. It is helpful to evaluate both
scoring systems with adjustment for primary malignancy depending on the clinical setting. Patients with Tomita
scores less than or equal to 8 and Tokuhashi scores greater than or equal to 6 are recommended to undergo
surgical management.
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The primary goals of surgery for spinal metastasis are
generally pain relief and the preservation of ambulatory
functions [1]. In the last 2 decades, the development of
surgical methods has resulted in improved postoperative
quality of life. However, the prognostic factors and the
role of surgery in the treatment of metastatic spinal dis-
eases remain unclear. Several authors suggested predic-
tive systems to evaluate life expectancy, which helps in
decision-making concerning the subsequent treatment
strategy after the development of metastatic spinal dis-
eases. In addition, the Tomita and Tokuhashi systems
have been widely accepted in clinical settings [2,3]. How-
ever, the systems greatly differ in their use of scoring
parameters and the relative importance of various pre-
operative factors.
This aim of this study is to determine the effectiveness to
determine the effectiveness of the Tomita and Tokuhashi
scoring systems in determining patient prognosis. We
also evaluated the validity and predictive value of the
Tomita and Tokuhashi scoring systems. We discuss se-
veral aspects to adjust both scoring systems to improve
their prediction of survival. Moreover, we suggest modi-
fied criteria for selecting treatment strategies according
to the adjusted scores.
Methods
Patient selection
The outcomes of 153 patients who underwent surgical
treatment for metastatic spinal diseases between January
2006 and June 2011 were retrospectively reviewed. Pa-
tients with spinal metastasis who had undergone previ-
ous surgery, children less than 18 years old, and patients
lost to follow-up were excluded from the study. Finally,
112 patients were enrolled in our study. The records
of all patients were retrieved, and demographic data
were collected, including age, sex, affected period, and
surgical outcome. Relevant clinical data were obtained
through a review of the patients’ charts and operative
reports. The extent of surgical resection, use of any adju-
vant therapy, length of follow-up, evidence of recur-
rence, and complications were also noted. The study was
independently reviewed and approved by the institu-
tional review boards of Samsung Medical Center.
Surgery and adjuvant therapy
All patients were evaluated on plain radiographs, com-
puted tomography (CT), and magnetic resonance im-
aging of the spine. Bone scintigraphy and positron
emission-CT, and CT of the chest, abdomen, and brain,
were also performed to evaluate systemic metastasis.
Candidates for surgical management were carefully
selected on the basis of the following surgical indicators:
1) more than 6 months of life expectancy as predictedby medical oncologists based on general performance
and response to chemotherapy; 2) the presence of un-
endurable severe pain; and 3) the presence of neurologic
deficits. Each patient had undergone surgical treatment
with appropriate procedures depending on the surgeon’s
decision. The operative procedures included excisional
surgery with/without spondylectomy and palliative sur-
gery with/without posterior fixation. The extent of surgi-
cal resection was classified into four types as follows:
type 1, total en bloc resection; type 2, marginal or piece-
meal lesionectomy; type 3, decompression with posterior
fixation; and type 4, decompression without internal fix-
ation. Adjuvant treatments including chemotherapy or
radiation therapy were performed in consideration of the
individual disease course. After surgery, the patients
were regularly followed up every month. The length of
the follow-up period was defined as the period from the
date of surgery to the patient’s most recent clinic visit.
Analysis of prognostic factors related to survival
Several preoperative variables were analyzed, including
age, gender, the type of primary malignancy, the involved
spinal level, and the type of operation. Other factors in-
cluding the interval between the diagnosis of primary
malignancy and that of spinal metastasis and the interval
between the diagnosis of spinal metastasis and the oper-
ation date were also analyzed as independent prognostic
variables. The interval between the diagnoses of primary
malignancy and spinal metastasis was classified into 3
categories as follows: 1) metastasis already present at the
time of the primary diagnosis (with no time interval), 2)
early metastasis (within 1 year), and 3) late metastasis
(after 1 year). An interval of less than a month between
the diagnoses was considered to indicate that spinal me-
tastasis was already present. The interval between the
detection of metastasis and surgery was classified as 1)
immediate surgery and 2) delayed surgery depending on
whether preoperative adjuvant treatment was needed.
An interval of less than a month between the detection
of spinal metastasis and surgery was considered immedi-
ate surgery. The overall survival period was analyzed
according to the type of primary malignancy. The histo-
logical scoring criteria of the Tomita and Tokuhashi sys-
tems were re-classified according to the survival period
for each cancer type assessed in the present study.
Analysis of the validity of the scoring systems
For preoperative prognostic scoring, the modified Toku-
hashi and Tomita scoring systems were used [2,3]. For
each primary malignancy, new scoring criteria were ap-
plied in each system according to the survival results
of this study. Each revised scoring system was adjusted
in line with the scoring principle described in the ori-
ginal articles. The validity of the prognostic scores was
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the scores. The mean or median survival and hazard ra-
tio in each scoring group were calculated and compared
with previously reported values.
Statistical analyses
Student’s t-test was used for continuous and parametric
values, and the chi-squared test and Fisher’s exact test
were used for categorical dates and values, respectively.
Overall survival was estimated using the Kaplan-Meier
method. The log-rank test and Cox proportional hazards
model were utilized to determine factor-influenced pro-
gression. Correlation studies were performed using
Spearman’s rank correlation and simple regression to in-
vestigate the relationships between overall survival and
the prognostic scores. Statistical analysis was conducted
using commercially available software (SPSS statistics
version 20.0; SPSS, Chicago, IL). A p-value < 0.05 was
regarded as statistically significant.
Results
Patient demographics
Overall, the outcomes of 112 consecutive patients (88
males and 24 females) with a median age of 57 years
(range, 28–76 years) were retrospectively reviewed.
Spinal metastasis was detected at the cervical level in 20
patients, the thoracic level in 49 patients, the lumbosa-
cral level in 27 patients, and multiple levels in 11 pa-
tients. The most common types of primary malignancy
were lung, liver, and gastrointestinal cancers, which were
observed in 23, 19, and 19 patients, respectively. The
demographic data of the study population are summa-
rized in Table 1.
Surgical results
En bloc resection (type 1) of tumors was achieved in 3
patients, and marginal or intralesional resection (type 2)
was performed in 56 patients. Palliative surgery was per-
formed in 53 patients, including 41 patients who under-
went decompression with fixation (type 3) and 12
patients who underwent decompression without fixation
(type 4). In our series, the 30-day morbidity rate was
16.1% (16 cases), and the 30-day mortality rate was 4.5%
(5 cases). Surgical complications involved pneumonia in
6 patients, wound infection/dehiscence in 5 patients,
and postoperative hematoma, deep vein thrombosis, and
cerebrospinal fluid leakage in 2 patients. Other compli-
cations included urinary tract infection, gastrointestinal
bleeding, and screw loosening or malposition in 3 pa-
tients. Life-threatening complications, such as sepsis,
acute respiratory failure, myocardial infarction, pulmon-
ary embolism, and intracranial hemorrhage, were also
present in 5 patients. Four patients (3.6%) experienced
surgical complications requiring a second surgery, suchas wound dehiscence, postoperative bleeding, and cere-
brospinal fluid leakage. The surgical results of various
primary malignancies, including postoperative complica-
tion, mortality, and the 1-year survival rate, are summa-
rized in Table 2.
Prognostic value of preoperative factors
All 112 candidates were evaluated for follow-up analysis.
The 1-year survival rate was 26.8%. The last evaluation
was performed in June 2012, producing a median
follow-up time of 5.8 months after the operation (range,
0.5–75.1 months). Ninety-nine patients died during the
follow-up period. The most common causes of death
were major organ failure due to multiple metastases.
Two patients died because of septic shock and another 2
patients because of myocardial infarction and pulmonary
embolism, respectively. 1 patient died because of brain
metastasis.
In univariate analysis, age (p = 0.235), gender (p = 0.460),
the involved spinal level (p = 0.373), and the type of surgi-
cal methods (p = 0.228) had no significant relationship
with survival (Table 3). However, the interval from the
diagnosis of primary malignancy to that of spinal metasta-
sis (p = 0.023) and the interval from the diagnosis of spinal
metastasis to surgery (p = 0.039) were significantly related
to survival. The survival period after surgery was longer in
patients in whom spinal metastasis was present at the
time of primary malignancy diagnosis and in those with
late metastasis than in those with early metastasis. Con-
cerning the timing of surgery, immediate surgery within a
month was associated with a better prognosis than de-
layed surgery.
The mean survival of the 112 patients according to the
type of primary malignancy is summarized in Table 4.
Primary malignancy was classified as favorable, inter-
mediate, or poor according to the mean survival period.
Lymphoma, multiple myeloma, thyroid cancer, and
breast cancer had favorable prognoses with a mean sur-
vival of 54.4 months (95% confidence interval [CI] =
39.5–69.2 months). Cancers of the uterus, liver, pros-
tate, and kidney and other unspecified malignancies had
an intermediate prognosis with a mean survival of
14.7 months (95% CI = 10.1–19.4 months). Lung,
gastrointestinal, hepatobiliary, and bladder cancers had
a poor prognosis with a mean survival of 5.2 months
(95% CI = 3.9–6.4 months). The hazard ratios of the fa-
vorable, intermediate, and poor prognosis groups were
1, 5.21, and 12.86, respectively.
Validity of the scoring systems
The predictive value of the Tokuhashi and Tomita scores
was analyzed with/without adjustment for the primary
malignancy. For Tokuhashi scores, each scoring system
was linearly correlated with survival on a logarithmic
Table 1 Demographic data of the study population
Primary
site
Age Gender Spinal level
Total
≤65 >65 Male Female Cervical Thoracic Lumbo-sacral Multiple
Lung 21 2 17 6 8 10 3 2 23
Liver 18 1 16 3 6 8 5 0 19
Rectum 6 3 6 3 1 2 6 0 9
Kidney 6 1 7 0 0 1 4 2 7
Prostate 6 0 4 2 0 3 2 1 6
Colon 3 2 3 2 1 2 2 0 5
Breast 0 5 5 0 1 2 2 0 5
MM 4 1 5 0 1 4 0 0 5
Stomach 4 0 2 2 1 2 1 0 4
Uterus 0 4 4 0 0 2 0 2 4
Head/Neck* 4 0 3 1 1 3 0 0 4
GB/Biliary 1 2 3 0 0 3 0 0 3
Esophagus 3 0 1 2 0 2 0 1 3
Mediastinal† 3 0 3 0 0 2 0 1 3
Lymphoma 3 0 3 0 0 2 1 0 3
MPNST 2 0 2 0 1 0 1 0 2
Thyroid 0 2 1 1 0 1 0 1 2
Bladder 0 1 0 1 0 1 0 0 1
Others‡ 3 1 2 2 0 3 0 1 4
Total 87 25 87 25 21 53 27 11 112
Results are presented as number of patients.
*Nasopharyngeal cancer, glottic cancer, soft palate cancer; †thymoma, mesothelioma; ‡pancreatic cancer, urethral cancer, adrenal cancer, melanoma. MM, multiple
myeloma; GB, gall bladder; MPNST, malignant peripheral nerve sheath tumor.
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before adjustment (p = 0.001) and 0.853 after adjustment
(p < 0.001). In simple regression analysis, the coefficient
of determination (R2) was 0.624 before adjustment
(p = 0.001) and 0.727 after adjustment (p < 0.001). After
adjustment, the Tokuhashi scores were more strongly
correlated with survival than those before adjustment.
On the contrary, the mean survival predicted by each
Tomita score displayed no difference between before
and after adjustment. For Tomita scores, the correlation
coefficient on a logarithmic scale was −0.994 (p < 0.001),
which indicated a stronger correlation than the original
and adjusted Tokuhashi scores (Figure 1B). R2 as deter-
mined by simple regression analysis was 0.989 (p < 0.001).
Predictive value of the scoring groups
Patients were classified into prognostic groups according
to their Tokuhashi and Tomita scores (Table 5). Tokuhashi
scores were grouped as follows: 0–8, 9–11 and 12–15.
The mean survival times for these groups were 37.1,
32.8 and 9.4 months, respectively, before adjustment
(Figure 2A), and 38.3, 26.9 and 9.4 months, respectively,
after adjustment. However, the similarity of survivalbetween before and after adjustment was improved after
adjustment upon reclassification of the scores into
groups of 0–5, 6–9 and 10–15 (Figure 2B). For the re-
classified Tokuhashi scoring groups, the mean survival
times were 36.5, 12.9, and 4.4 months, respectively,
for the 3 groups (Figure 2C). In Spearman’s correlation
analysis, the correlation between the estimated survival
and the scoring groups was insignificant for group 2
(p > 0.050), but this score became significant after regroup-
ing (p = 0.001). The hazard ratios for the adjusted and
regrouped Tokuhashi scoring groups were 1, 2.42, and
6.17, respectively.
Tomita scores were grouped as follows: 2–3, 4–5, 6–7,
and 8–10. The mean survival ties for these 4 groups were
53.6, 27.0, 9.0, and 4.6 months, respectively (Figure 3A).
Tomita scores were also regrouped into ranges of 2–3, 4–
5, 6–8, and 9–10 based on the mean survival (Figure 3B).
After regrouping, the mean survival times were 8.4 months
for the 6–8 score group and 2.6 months for the 9–10
score group (Figure 3C). The hazard ratios for the 4
groups were 1, 3.30, 6.96, and 12.65, respectively, before
regrouping and 1, 3.33, 7.65, and 42.62, respectively, after
regrouping.











months†Excisional Op Palliative Op
Type 1 Type 2 Type 3 Type 4
Lung 0 9 11 3 8.7 8.7 13.0 4.3 (0.7 - 20.1)
Liver 0 10 5 4 10.5 5.3 31.6 8.5 (0.6 - 45.7)
Rectum 0 7 2 0 11.1 0 0 3.3 (1.0 - 4.8)
Kidney 0 4 3 0 0 0 14.3 9.2 (5.0 - 26.2)
Prostate 0 1 5 0 50.0 0 16.7 5.4 (3.9 - 36.7)
Colon 0 3 2 0 20.0 0 80 33.4 (5.6 - 46.2)
Breast 1 4 0 0 0 0 0 4.7 (4.5 - 10.4)
MM‡ 0 4 1 0 0 0 100 27.8 (17.5 - 53.7)
Stomach 0 3 1 0 0 0 0 4.3 (2.7 - 10.5)
Uterus 1 2 1 0 75 0 25.0 7.6 (2.1 - 40.4)
Head/Neck 1 2 1 0 50 0 50.0 26.8 (3.9 - 48.5)
GB/Biliary 0 1 1 1 66.7 33.3 0 4.5 (0.7 - 5.3)
Esophagus 0 2 1 0 33.3 0 33.3 2.3 (2.1 - 13.5)
Mediastinal 0 0 2 1 0 33.3 33.3 6.3 (0.5 - 32.3)
Lymphoma 0 1 2 0 33.3 0 66.7 60.9 (11.6 - 75.1)
MPNST 0 2 0 0 0 0 50.0 24.5 (3.1 - 45.9)
Thyroid 0 0 1 1 0 0 100 45.9 (17.1 - 74.7)
Bladder 0 0 0 1 0 0 0 2.7
Others 0 1 2 1 0 0 25.0 6.8 (2.0 - 16.5)
Total 3 56 41 12 16.1 4.5 27.7 5.9 (0.5 - 75.1)
*1-year survival rate; †median follow-up period with ranges; MM, multiple myeloma; GB, gall bladder; MPNST, malignant peripheral nerve sheath tumor.
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In this study, several preoperative variables were exam-
ined to identify their prognostic value. According to our
results, gender and age have no significant relationship
with survival, which is consistent with previous studies.
However, it has been reported that patients younger
than 65 years have a significantly high level of satisfac-
tion after surgical management [1]. The interval between
the primary diagnosis and the diagnosis of spinal metasta-
sis was presently identified as an independent prognostic
factor (p = 0.042). This interval might be also relevant to
cancer progression, which can be easily assessed regard-
less of other clinical findings. The timing of the operation
was also significantly relevant to survival (p = 0.027),
which implies that the role of surgery in the treatment of
metastatic spinal diseases is not limited to improvement
of a patient’s quality of life, but it may also be related to
life expectancy.
Although various scoring systems have been described
in previous studies, a few selected systems have been
widely used and recommended by the Global Spinal
Tumor Study Group [4]. Tokuhashi et al. designed a scor-
ing system to predict the prognosis of patients with meta-
static spinal diseases and select the most appropriatetreatment strategy [2]. Tomita et al., who implied that the
Tokuhashi scoring system does not consider the relative
importance of individual prognostic factors, suggested
another scoring system that focused on surgical strat-
egies [3]. The Tomita scoring system consists of only 3
prognostic factors, namely the grade of the primary ma-
lignancy, presence of visceral metastases, and presence
of bone metastases.
In both scoring systems, the type or grade of the pri-
mary malignancy is one of the most important factors
affecting survival. Tokuhashi et al. assigned 0 points for
a mean survival of less than 6 months, 1 point for a
mean survival of approximately 6 months, 2 points for
an unspecified mean survival, 3 points for a mean sur-
vival of less than 12 months, and 4 or 5 points for a
mean survival of more than 12 months [3]. The Tomita
score of 1, 2, and 4 for primary malignancies were based
on hazard ratios obtained using Cox regression analysis
(1, 1.82, and 4.08, respectively, in the original article) [1].
However, the survival results for each cancer group were
not consistent between those studies. For example, rectal
cancer was categorized into the mild prognostic group
in the Tokuhashi system, whereas it was classified as
a high-grade malignancy in the Tomita system. The
Table 4 Scoring based on the primary malignancy
Primary
malignancy No.
Survival period (months) Tokuhashi score Tomita score
Prognosis
Mean (95% CI) Median (95% CI) Original Adjusted Original Adjusted
Lymphoma 3 53.9 (20.1 - 87.8) - - 5 - 1
Favor
MM* 5 46.5 (33.8 - 59.2) - - 5 - 1
Thyroid 2 45.9 (5.9 - 85.9) 17.1 5 5 1 1
Breast 5 31.4 (15.4 - 47.4) - 5 5 1 1
Uterus 4 14.4 (0.0 - 29.5) 3.9 (0.0 - 12.9) 3 4 2 2 Intermediate
Liver 19 12.2 (6.6 - 17.7) 8.5 (5.6 - 11.5) 1 4 4 2
Prostate 6 10.9 (1.6 - 20.2) 5.1 (4.1 - 6.0) 5 3 1 2
Kidney 7 10.8 (5.9 - 15.7) 9.2 (5.2 - 13.3) 3 3 2 2
Lung 23 6.0 (3.7 - 8.3) 4.3 (1.3 - 7.3) 0 1 4 4
Poor
Esophagus 3 6.0 (0.0 - 13.4) 2.3 (2.0 - 2.6) 0 1 - 4
Colon 5 6.0 (3.8 - 8.2) 4.7 (4.5 - 4.9) 2 1 4 4
Stomach 4 5.5 (2.0 - 8.9) 3.4 (0.8 - 5.9) 0 0 - 4
GB/Biliary 3 3.5 (0.7 - 6.3) 4.5 (0.0 - 10.7) 1 0 - 4
Rectum 9 3.1 (2.1 - 4.0) 3.3 (2.4 - 4.3) 4 0 - 4
Bladder 1 2.7 2.7 0 0 - 4
Others* 13 18.9 (7.3 - 30.4) 6.3 (0.0 - 14.3) 2 2 - 2 Intermediate
Overall 112 17.3 (12.6 - 22.1) 5.8 (5.0 - 6.7)
Primary malignancy was categorized according to the Tokuhashi score (0 to 5) or Tomita score (1, 2, or 4). The scores for certain primary malignancies, including
uterine, liver, and prostate cancers, were reassigned for adjustment. The scores for colon and rectal cancers in the Tokuhashi system were reassigned to indicate a
worse prognosis in line with the Tomita system. *Other types of primary malignancy: head and neck region, mediastinum, and other malignancies, that is,
pancreatic cancer, urethral cancer, adrenal cancer, and melanoma. MM, multiple myeloma; GB, gall bladder; MPNST, malignant peripheral nerve sheath tumor.
Dash means no value for parameter.
Table 3 Survival analysis of each preoperative factor
Preoperative factor No. ofpatients
Survival period (months)
P value
Mean (95% CI) Median (95% CI)
Age Less than 65 87 19.4 (13.6 - 25.2) 5.8 (4.3 - 7.3) 0.235
65 or more 25 8.6 (5.7 - 11.6) 6.1 (3.8 - 8.5)
Gender Male 87 16.5 (11.3 - 21.7) 5.8 (4.9 - 6.8) 0.460
Female 25 20.7 (9.9 - 31.4) 8.0 (2.0 - 13.9)
Spinal level Cervical 21 9.9 (3.6 - 16.2) 4.2 (3.7 - 4.6) 0.373
Thoracic 53 17.7 (11.1 - 24.3) 6.5 (3.4 - 9.7)
Lumbosacral 27 14.9 (8.5 - 21.3) 5.9 (4.9 - 6.8)
Multiple 11 18.3 (2.4 - 34.1) 7.7 (3.4 - 11.9)
Operation type Type 1 3 35.7 (16.2 - 55.3) N/A 0.228
Type 2 56 14.1 (9.7 - 18.6) 5.6 (2.2 - 9.0)
Type 3 41 17.6 (9.6 - 25.7) 6.1 (5.3 - 6.9)
Type 4 12 8.8 (2.1 - 15.6) 5.3 (0.2 - 10.3)
Time interval to metastasis* None 36 24.4 (14.7 - 34.1) 7.8 (1.9 - 13.8) 0.023*
<1 year 20 7.4 (2.9 - 11.9) 5.1 (2.0 - 8.2)
>1 year 56 17.3 (10.7 - 24.0) 5.5 (4.3 - 6.8)
Time interval to operation† Immediate 84 19.7 (13.9 - 25.5) 6.2 (3.8 - 8.7) 0.039†
Delayed 28 8.1 (4.5 - 11.7) 5.0 (3.0 - 7.1)
Total 112 17.3 (12.6 - 22.1) 5.8 (5.0 - 6.7)
*The interval between the diagnosis of primary malignancy and that of spinal metastasis; †the interval between the diagnosis of spinal metastasis and surgery:
these intervals were significantly associated with survival according to the log-rank test. N/A, estimation data not available due to the lack of uncensored cases.
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Figure 1 Simple linear regression of two scoring systems. (A) Tokuhashi scores and mean survival. The coefficient of determination (R2) was
0.6238 (red line) before adjustment and 0.7274 (blue line) after adjustment. (B) Tomita scores and mean survival. R2 according to simple
regression analysis was 0.9885. There was no difference between Tomita scores before and after adjustment.
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was also inconsistent with the survival data from other
studies [5].
In our study, the survival results for each malignancy
were more consistent with the Tomita system. We reclas-
sified the scoring of primary malignancy based on our re-
sults; i.e., colorectal cancer was given a score of 0 points
instead of 2–4 points, and liver cancer was given a score
of 4 points instead of 1 point. As the prognosis and disease
course vary widely depending on the characteristics of
the primary malignancy, several recent studies discussedTable 5 Comparison of the validity of Tokuhashi and Tomita

























*Reclassified groups after reorganization of prognostic scores. †P-value obtained by
data not available due to the lack of uncensored cases. Dash means no value for paprognostic scoring focused on individual cancer groups
[6,7]. Recently, the development of new cancer therapies
places the scoring systems in a new scenario, implying a
need for reassessment of its current usefulness. Recent
studies have shown both favorable and unfavorable results
in this paradigm. Accordingly, the scoring for primary ma-
lignancy should be carefully evaluated in consideration of
each institute’s clinical settings.
Comparing the validity of the 2 scoring systems is
not a simple task. Several institutes reported their clin-




Mean (95% CI) Median (95% CI)
37.1 (18.9 - 55.3) 17.1 (5.9 - 28.2) - 0.000
32.8 (18.6 - 47.0) 10.7 (9.1 - 12.3) 1.23 0.654
9.4 (6.6 - 12.3) 5.3 (4.4 - 6.1) 3.17 0.004
38.3 (21.6 - 54.9) 17.1 (5.0 - 29.1) - 0.000
26.9 (15.1 - 38.8) 8.9 (3.0 - 14.8) 1.67 0.222
9.0 (6.1 - 11.9) 4.9 (4.1 - 5.6) 3.56 0.001
36.5 (24.9 - 48.1) 14.9 (5.3 - 24.5) - 0.000
12.9 (8.4 - 17.3) 6.2 (4.6 - 7.8) 2.42 0.002
4.4 (3.3 - 5.5) 3.9 (2.1 - 5.8) 6.17 0.000
53.6 (36.3 - 70.8) N/A - 0.000
27.0 (16.2 - 37.8) 10.0 (7.7 - 12.4) 3.30 0.028
9.0 (5.7 - 12.4) 5.3 (4.4 - 6.1) 6.96 0.000
4.6 (3.2 - 6.0) 3.3 (2.2 - 4.5) 12.65 0.000
53.6 (36.3 - 70.8) N/A - 0.000
27.0 (16.2 - 37.8) 10.0 (7.7 - 12.4) 3.33 0.027
8.2 (5.7 - 10.6) 5.5 (4.5 - 6.5) 7.65 0.000
2.4 (1.7 - 3.1) 2.3 (1.7 - 2.9) 42.62 0.000
Cox regression; P <0.050 denotes statistical significance (Sig) N/A, estimation
rameter.
Figure 2 Estimated survival curves of the Tokuhashi scoring systems. A) Overall survival for the original Tokuhashi scoring system.
B) Regrouping into score groups of 0–5, 6–9, and 10–15 based on the survival data. C) Overall survival for the adjusted and regrouped
scoring systems.
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accuracy rate of the Tomita or Tokuhashi scoring system
in series of patients treated with earlier cancer protocols,
Padalkar et al. compared the usefulness of the two scor-
ing system in a prospective series of 102 patients under-
going surgery for spinal metastasis. Type of primary
tumor was not found to be significantly associated with
survival according to the revised Tokuhashi scoring sys-
tem (P = .9131,). Stepwise logistic regression revealed
that the Tomita score correlated more closely with sur-
vival than the Tokuhashi score. They suggested that
Tomita scores had a stronger correlation with survival
than Tokuhashi scores [5]. Conversely, Ulmar et al. re-
ported that Tokuhashi scores appear to be more valu-
able than Tomita scores in survival analysis of 37
consecutive patients with spinal metastases secondary to
renal cancer. [12]. Zou et al. reported that Tokuhashi
scores more accurately predicted short-term survival,
whereas Tomita scores were more useful for predicting
long-term survival [13].
Hessler et al. evaluated the reliability of the Tokuhashi
scoring system in patients with lung cancer. The authors
concluded that the Tokuhashi scoring system is not an
optimal tool for decision-making in patients with spinal
metastasis of lung cancer, and they mentioned a risk ofFigure 3 Estimated survival curves of the Tomita scoring systems. A)
into score groups of 2–3, 4–5, 6–8, and 9–10 based on the survival data. C)undertreatment in certain patients with unfavorable scores
who ultimately survived longer than 12 months [14]. In
our study, Tomita scores had a stronger correlation with
mean survival (R2 = 0.9885). Although Tokuhashi scores
had a weaker correlation with mean survival, the correl-
ation was improved after adjustment of the scoring based
on the primary malignancy (R2 = 0.6238–0.7274). There-
fore, we suggest that the Tomita system is a simpler and
more accurate tool in preoperative evaluation for predict-
ing life expectancy.
Another important issue in planning treatment strategies
is deciding between surgical management and supportive
care. It is generally accepted that surgical management
should be considered for patients with a life expectancy of
at least 3 months [4]. Tokuhashi et al. predicted life expect-
ancy by grouping their scores, resulting in scores of 0–8
for a mean survival of less than 6 months, 9–11 for a mean
survival of 6–12, and 12–15 for a mean survival exceeding
12 months [3]. According to Tokuhashi et al., surgical man-
agement is not recommended for patients with Tokuhashi
scores of 0–8, as their life expectancy is less than 6 months.
Tomita et al. also grouped their scores, resulting in scores
of 2–3 for a mean survival of 49.9 months, 4–5 for a mean
survival of 23.5 months, 6–7 for a mean survival of
15.0 months, and 8–10 for a mean survival of 5.9 monthsOverall survival for the original Tomita scoring system. B) Regrouping
Overall survival for the regrouped Tomita scoring system.
Figure 4 Proposed treatment strategy according to the A) Tokuhashi and B) Tomita score systems. Tokuhashi scores of 10–11 were
reclassified to recommend excisional surgery (either en bloc or intralesional resection) instead of palliative surgery (oblique lines). A Tomita score
of 8 and Tokuhashi scores of 10–11 have been reclassified to recommend palliative surgery instead of conservative treatment (oblique lines).
Kim et al. World Journal of Surgical Oncology 2014, 12:245 Page 9 of 10
http://www.wjso.com/content/12/1/245[2]. They recommended that patients with Tomita scores
of 8–10 should receive supportive care. However, our re-
sults illustrated that more patients can be considered for
surgical management than identified by both scoring sys-
tems. Our data indicated that patients with a Tomita score
of 8 have an estimated survival exceeding 6 months, which
was obviously different from the estimated survival of pa-
tients with scores of more than 9. We suggest that a
Tomita score of 8 should be reclassified into the upper
group, in which patients are recommended to consider
palliative surgery rather than supportive care. Recently,
several authors reported that the Tokuhashi system was
not highly accurate for predicting survival in patients with
spinal metastasis, treated or not surgically, and it was
particularly imprecise in patients with an intermediate
score (9–11 points) [6,15]. In our study, because scores of
10–11 were associated with a mean survival exceeding
12 months in the Tokuhashi system, these scores were re-
classified to recommend excisional surgery (either en bloc
or intralesional resection) instead of palliative surgery.
Furthermore, patients with Tokuhashi scores of 6–8 had a
life expectancy exceeding 6 months, and they should be
reclassified into the next survival category recommending
more aggressive treatment (Figure 4).
Conclusions
In conclusion, the interval between the diagnosis of the
primary malignancy and that of spinal metastasis and the
interval between the diagnosis of spinal metastasis and
surgery were identified as independent prognostic factors
that are practically simple to assess. Concerning the scor-
ing systems, Tomita scores more accurately predictedsurvival than Tokuhashi scores. We also suggest that pa-
tients with Tomita scores of 8 or less and Tokuhashi
scores of 6 or more should be considered for surgical
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